Nonapeptide of Formula I, Pharmaceutical Compositions and Methods for Preparation Thereof

1. The invention provides a novel nonapeptide which acts as a microtubule stabilizer and excellent neuroprotector, having better neuroprotection than any other earlier reported peptide in this field.

2. Peptide based therapeutic has always excellent bioavailability.

3. It is simple to synthesize and the product is inexpensive.

4. Easy to modify the peptide sequence according to the pharmacophore requirement.

5. Novel nonapeptide exhibits dual property like stabilizes microtubule as well as provides excellent protection to neuron cells againstAβ infection.

6. This novel peptide based drugs can be used as a potential therapy for Alzheimer’s disease (AD

The invention relates to a novel short nonapeptide, designed from the taxol binding cavity of β-tubulin. It has the ability to bind at taxol pocket of β-tubulin with a significant binding affinity and promotes microtubule polymerization. In addition, this peptidebinds to the 17-21 region of amyloid beta, inhibits acetylcholinesterase (AChE) induced amyloid beta (Aβ) aggregation by interacting at the peripheral anionic site (PAS) of AChE, enters into the derived neurons, promotes neurite growth, provides microtubule stabilization and shows significant neuroprotection against nerve growth factor (NGF) deprived neurons. Moreover, it doesn’t show any toxicity to both rat pheochromocytoma (PC12) derived neurons as well as primary cortical neurons.

This novel peptide based drugs can be used as a potential therapy for Alzheimer’s disease (AD).